- Volume 94, Current Issue
- Vol 28, October 2019
- Vol 27, September 2019
- Vol 26, August 2019
- Vol 25, July 2019
- Vol 24, June 2019
- Vol 23, May 2019
- Vol 22, April 2019
- Vol 21, March 2019
- Vol 20, February 2019
- Vol 19, January 2019
- Vol 18, December 2018
- Vol 17, November 2018
- Vol 16, October 2018
- Vol 15, September 2018
- Vol 14, August 2018
- Vol 13, July 2018
- Vol 12, June 2018
- Vol 11, May 2018
- Vol 10, April 2018
- Vol 9, March 2018
- Vol 8, February 2018
- Vol 7, January 2018
- Vol 6 No 12, December 2017
- Vol 6 No 11, November 2017
- Vol 6 No 10, October 2017
- Vol 6 No 9, September 2017
- Vol 6 No 8, August 2017
- Vol 6 No 7, July 2017
- Vol 6 No 6, June 2017
- Vol 6 No 5, May 2017
- Vol 6 No 4, April 2017
- Vol 6 No 3, March 2017
- Vol 6 No 2, February 2017
- Vol 6 No 1, January 2017
- Vol 5 No 12, December 2016
- Vol 5 No 11, November 2016
- Vol 5 No 10, October 2016
- Vol 5 No 9, September 2016
- Vol 5 No 8, August 2016
- Vol 5 No 7, July 2016
- Vol 5 No 6, June 2016
- Vol 5 No 5, May 2016
- Vol 5 No 4, April 2016
- Vol 5 No 3, March 2016
- Vol 5 No 2, February 2016
- Vol 5 No 1, January 2016
- Vol 4 No 12, December 2015
- Vol 4 No 11, November 2015
- Vol 4 No 10, October 2015
Cover Story Current Issue

Cytosolic phosphoenolpyruvate carboxykinase (PCK1) catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) and CO2 using GTP as a phosphate donor. PCK1 is tightly regulated at the transcriptional level and is highly induced during fasting, especially in the liver.
Current Issue
LOX-1 rewires glutamine ammonia metabolism to drive liver fibrosis
- Abstract
Objective
Liver fibrosis is a crucial condition for evaluating the prognosis of chronic liver disease. Lectin-1ike oxidized low density lipoprotein receptor-1 (LOX-1) has been shown potential research value and therapeutic targeting possibilities in different fibrotic diseases. However, the role of LOX-1 and the underlying mechanisms in liver fibrosis progression remain unclear.
Methods
LOX-1 expression was detected in liver tissues from patients and rodents with liver fibrosis. LOX-1 knockout rats were subjected to CCl4 or methionine and choline-deficient diet (MCD) to induce liver fibrosis. Transcriptomic and metabolomics analysis were used to investigate the involvement and mechanism of LOX-1 on liver fibrosis.
Results
We found that LOX-1 exacerbated liver fibrosis by promoting hepatic stellate cells (HSCs) activation. LOX-1 deletion reversed the development of liver fibrosis. We further verified that LOX-1 drove liver fibrosis by reprogramming glutamine metabolism through mediating isoform switching of glutaminase (GLS). Mechanistically, we revealed the crucial role of the LOX-1/OCT1/GLS1 axis in the pathogenesis of liver fibrosis. Moreover, LOX-1 rewired ammonia metabolism by regulating glutamine metabolism-urea cycle to drive the progression of liver fibrosis.
Conclusions
Our findings uncover the pivotal role of LOX-1 in the progression of liver fibrosis, enrich the pathological significance of LOX-1 regulation of hepatic ammonia metabolism, and provide an insight into promising targets for the therapeutic strategy of liver fibrosis, demonstrating the potential clinical value of targeting LOX-1 in antifibrotic therapy.
Articles in Press
LOX-1 rewires glutamine ammonia metabolism to drive liver fibrosis
- Abstract
Objective
Liver fibrosis is a crucial condition for evaluating the prognosis of chronic liver disease. Lectin-1ike oxidized low density lipoprotein receptor-1 (LOX-1) has been shown potential research value and therapeutic targeting possibilities in different fibrotic diseases. However, the role of LOX-1 and the underlying mechanisms in liver fibrosis progression remain unclear.
Methods
LOX-1 expression was detected in liver tissues from patients and rodents with liver fibrosis. LOX-1 knockout rats were subjected to CCl4 or methionine and choline-deficient diet (MCD) to induce liver fibrosis. Transcriptomic and metabolomics analysis were used to investigate the involvement and mechanism of LOX-1 on liver fibrosis.
Results
We found that LOX-1 exacerbated liver fibrosis by promoting hepatic stellate cells (HSCs) activation. LOX-1 deletion reversed the development of liver fibrosis. We further verified that LOX-1 drove liver fibrosis by reprogramming glutamine metabolism through mediating isoform switching of glutaminase (GLS). Mechanistically, we revealed the crucial role of the LOX-1/OCT1/GLS1 axis in the pathogenesis of liver fibrosis. Moreover, LOX-1 rewired ammonia metabolism by regulating glutamine metabolism-urea cycle to drive the progression of liver fibrosis.
Conclusions
Our findings uncover the pivotal role of LOX-1 in the progression of liver fibrosis, enrich the pathological significance of LOX-1 regulation of hepatic ammonia metabolism, and provide an insight into promising targets for the therapeutic strategy of liver fibrosis, demonstrating the potential clinical value of targeting LOX-1 in antifibrotic therapy.
Save the Date

12th Helmholtz
Diabetes Conference
22-24. Sep, Munich
You are what you eat
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.